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Abstract  
Bacterial meningitis is a serious disease that causes permanent dysfunction or death; adolescents 
and young adults carry the greatest risk.  The national Advisory Committee on Immunization 
Practices (ACIP) has released vaccine recommendations that include incorporation of meningitis 
vaccine in to the mandatory school vaccine schedule.  Throughout the nation, much of legislative 
policy has made meningitis vaccination a requirement for public school attendance.  Alaska does 
not have such policy; the purpose of the project was to address this policy need.  A secondary 
project goal was to increase community awareness of bacterial meningitis.  Project actions were 
divided into policy advocacy and community awareness.  Policy advocacy included the 
development of a Policy Brief to Persuade designed for the Alaska legislative health care 
committee members.  A legislative survey to assess willingness to incorporate a required 
meningitis vaccine schedule into existing Alaska vaccine policy was sent electronically with the 
policy brief.  Community awareness interventions included the development of a Meningitis 
Education Bundle for healthcare professionals and a Protect Alaska’s Future campaign.  The 
education bundle was distributed to local health establishments on Prince of Wales Island and the 
campaign information was distributed at the 2017 Prince of Wales Community Health Fair.  
Project outcomes demonstrated a lack of response to the policy survey.  Efforts must continue 
over time with a deliberate plan to gain legislative support for the incorporation of a meningitis 
vaccination schedule into existing Alaska vaccine policy, as recommended by the ACIP.  
Community awareness activities at the health fair were successful and should continue.   
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Vaccine Implementation: Alaska 2017 
 Meningococcal disease is defined as a bacterial infection by Neisseria Meningitidis 
involving several subtype strains, referred to as serotypes of this bacteria.  Neisseria 
Meningitidis overgrowth can manifest as meningitis, involving cerebral spinal fluid of the brain 
and spinal cord; as sepsis, involving a widespread blood stream infection with many adverse 
manifestations; or as pneumonia (Immunization Action Coalition [IAC], 2016).  Serotypes A, B, 
C, Y, and W-are thought most responsible for causing meningitis and sepsis (Center for Disease 
Control and Prevention [CDC], 2014; IAC, 2016; National Meningitis Association [NMA], 
2016).  Serotypes B, C, and Y are most prevalent in the United States, Alaska, and the United 
States (US) military (Broderick et al., 2015).  Meningitis illness develops rapidly without 
warning in healthy young individuals.  Permanent neurologic dysfunction, musculoskeletal 
deformity, and death are catastrophic consequences of meningitis infection (CDC, 2017; NMA, 
2016).  
 According to the Centers for Disease Control and Prevention’s Strategic Framework for 
Global Immunization (2016), “vaccine preventable diseases (VPD) can be controlled, eliminated, 
or eradicated with vaccines and vaccine initiatives” (p.9).  This was demonstrated by eradication 
of poliovirus infections in the United States following vaccine implementation.  Meningitis is a 
life-threatening condition that does not have a uniform mandatory vaccination schedule in the 
US (CDC, 2016).  According to Alaska’s State Epidemiology Department, Neisseria 
Meningitidis is a public health emergency, which requires mandatory reporting of all suspected 
or confirmed cases (Department of Health and Social Services [DHSS], 2015).   
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 In response to this public health emergency, 14 of 51 states (including the District of 
Columbia) developed a meningitis vaccine policy requiring that at least one dose of meningitis 
vaccine must be administered to a child by Grade seven (IAC, 2017).  In addition, 15 of 51 states 
require students entering colleges or universities be educated about meningitis prevention 
(transmission and vaccination) (IAC, 2017).  Twenty-two of 51 states require that students be 
educated about meningitis and provide proof of vaccination or a waiver.  Currently, Alaska only 
requires students residing on university campuses be counseled on the benefits of vaccination; 
the decision to vaccinate is left optional (Alaska State Legislature, 2015).  
Project Purpose, Aims, and Goals 
 Due to the high morbidity and mortality associated with meningococcal disease, the 
purpose of this project was to develop strategies to advocate for policy change for a mandatory 
meningitis vaccine schedule in Alaska.  Project aim was to improve health for young Alaskans 
utilizing primary prevention strategies.  The first goal involved increasing awareness of 
meningitis and prevention strategies available for Alaska.  The second goal was to gain support 
for a mandatory meningitis vaccination schedule.  Alaska should become the thirteenth state to 
mandate a meningitis vaccination in grades seven and twelve.  Legislative support and successful 
mandate for a vaccination schedule for meningitis in the State of Alaska was a goal of this 
project.  
 Policy change efforts to mandate a meningitis vaccination schedule that included the first 
vaccine required in seventh grade and a booster dose administered no later than Grade twelve 
were developed.  Additional mandates included a single vaccine for all students within higher 
education (university, vocational school, or otherwise) residing in campus housing.  Proof of 
vaccination or waiver must also be a requirement of higher education.  The project goal also 
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allowed for provisions that if a mandatory vaccine schedule for grades seven and twelve was not 
supported, the advocacy goal would focus on promoting students of higher education receiving at 
least one meningitis vaccination prior to on-campus living in the State of Alaska.  This includes 
proof of vaccination or waiver. 
Framework 
 Implementation of vaccine policy should follow a vaccine implementation framework.  
The CDC identified country ownership as a leading priority in promoting global health (CDC, 
2016).  Accountability begins on a state and national level first.  As state and nationally driven 
initiatives contribute to uniformity, progress is then made towards achieving global health.  
 The CDC global vaccine initiative framework includes programs, surveillance, vaccine 
delivery, and financial considerations and was utilized as the main framework for this project. 
More detailed public health frameworks presented by Erickson et al. (2005) and Gonzalez-
Lorenzo et al. (2014), coincide with the CDC’s global immunization framework to a large 
degree.  For the purposes of this project both frameworks were utilized as a comprehensive 
vaccine policy framework and included: burden of disease, vaccine characteristics, conformity of 
programs, equity of distribution, attitude/ political/legal/ ethical considerations, immunization 
strategy, effectiveness evaluation, cost, and use of resources (Erickson et al., 2005; Gonzalez-
Lorenzo et al., 2014).  
Literature Review  
Burden of Disease  
 Bacterial meningitis is spread from direct contact (such as kissing, sneezing, and 
coughing) and prolonged close quarter contact, related to transmission via airborne droplets 
(CDC, 2015; NMA, 2016).  An individual can carry the disease without showing signs of illness, 
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with Neisseria bacteria lying dormant in the oropharynx.  These individuals are known as 
carriers (CDC, 2016).  Adolescents and young adults (16 to 23 years of age) are the highest at-
risk population for both asymptomatically carrier status and for contracting meningitis (CDC, 
2015; IAC, 2016; NMA, 2016).  Environments such as schools, sports teams and dormitories 
have the potential to increase disease transmission. 
 Other risk factors for contracting bacterial meningitis include tobacco smoke exposure, 
being immunocompromised, and having a previous viral infection (IAC, 2016).  Research 
authorities are also examining a link between contracting meningitis secondary to a 
mononucleosis infection.  If this proves to be a substantial theory, that would make adolescents 
and young adults additionally more susceptible, as mononucleosis is also common in this age 
group.  
 According to the CDC, children 11 years and older are most afflicted by meningitis 
strains B, C, and Y, with two out of three cases occurring within these subtypes.  Ten percent to 
15% of subjects will die when infected with meningococcal disease.  Astoundingly, 11% to 19% 
of individuals who survive will have lasting sequela such as deafness, nervous system 
dysfunction, limb amputation, and/or brain damage (CDC, 2015; NMA, 2016).  The aftermath of 
the disease casts a monumental burden, entailing financial, emotional, and physical 
consequences. 
 Similar to tuberculosis, risk for acquiring bacterial meningitis is also heightened in tight-
knit community settings where close quarter gatherings are common (CDC, 2015; IAC, 2016).  
Situations whereby multiple individuals occupy a single residence pose a similar risk.  Increased 
risk for Alaska Natives can therefore be inferred due to the prevalence of communal potlatches 
and the occurrence of multiple families co-residing.  
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 Serotypes B, C, and Y are the most frequently occurring strains in the United States 
(CDC, 2014; IAC, 2016; NMA, 2016).  Serotypes A, B, C, Y, and W-are thought most 
responsible for causing bacterial meningitis leading to sepsis.  According to the Center for 
Disease Control and Prevention (2015), there were approximately 550 cases of meningitis 
reported in 2013.  Of these cases, two out of three were reportedly caused by serotypes B, C or 
Y.  This national serotype prevalence directly matches previously identified meningitis rates in 
children 11 years of age and older (CDC, 2014; IAC, 2016; NMA, 2016).  
 Vaccination has been proven to prevent meningococcal disease.  Subsequently, a global 
vaccination initiative is underway (CDC, 2016).  The Advisory Committee on Immunization 
Practices, the Centers for Disease Control and Prevention, the American Academy of Pediatrics, 
and the National Meningitis Association endorse routine administration of the Quadrivalent 
Meningococcal Vaccine as a primary means of prevention for children and young adults during 
the time they are most at risk for contracting bacterial meningitis.   
 Between the years of 2006 to 2013, 28 cases of bacterial meningitis were reported by the 
US military (Broderick et al., 2015).  All but one case was caused by serotypes B, C, or Y.  Since 
instituting a universal meningitis vaccination policy for all military personnel, rates of meningitis 
have decreased by more than 90%.  The US military now considers routine vaccination against 
meningitis a standard of care.    
 In Alaska, since 2004, 39 cases of invasive meningitis were reported and primarily 
involved serotypes B, C, or Y (DHSS, 2015).  The Alaska Department of Epidemiology has 
already deemed Neisseria meningitis a public health emergency.  Despite the epidemiologic 
emergency, Alaska remains a meningitis vaccine optional state.  
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Vaccine Characteristics  
 The Quadrivalent Meningococcal Vaccine contains bactericidal antibodies to 
meningococcal antigens for serotypes most responsible for affecting school-aged children and 
young adults (A, C, Y, and W) (Woo & Robinson, 2016).  Two versions of this vaccine 
technology are available; one unconjugated polysaccharide vaccine and a conjugated 
polysaccharide vaccine.  Menomune is not conjugated while Menactra is conjugated.  Menactra 
is delivered with Diphtheria Toxoid to improve immunology (CDC, 2016; Sanofi Pasteur Inc., 
2014).  Menactra has been approved for young children age nine months and older, while 
Menomune has been approved for children two years and older.  Both are considered safe for 
routine administration.  The protective qualities of Menactra are believed to extend up to five 
years, making a second booster dose midway in the at-risk period necessary (Sanofi Pasteur Inc., 
2014).  
 The meningitis vaccine carries very few risks.  Documented risks include localized site 
reactions such as tenderness, redness, and swelling and low-grade temperature (Sanofi Pasteur 
Inc., 2014; Sanofi Pasteur Inc., 2016; Woo & Robinson, 2016).  Other documented reactions 
shared between both vaccines (influenced by age) include diarrhea, headache, appetite loss, and 
crying.  Additionally, the Quadrivalent Meningococcal Vaccine may not provide adequate 
immunological response in some individuals, especially those immunocompromised (Sanofi 
Pasteur Inc., 2014; Sanofi Pasteur Inc., 2016).  Adverse reactions associated with vaccination are 
also seen in persons with a history of Guillain-Barre syndrome.  However, these occurrences are 
not adequate reasons to withhold or decline vaccination.  Vaccination is contraindicated if the 
patient has a history of a previous allergic reaction to the meningitis vaccine or components. 
Standard vaccine administration includes examination of allergies, acknowledgement of past 
VACCINE IMPLEMENTATION: ALASKA 2017 13 
medical history, and calculation of risk factors that prioritizes patient safety as followed with any 
routine vaccination.  
 Routine vaccination against B serotype is not advised (AAP, 2016; CDC, 2016).  This 
vaccine is reserved for times of outbreak or when a patient presents with unique risks for 
contracting serotype B meningitis.  Due to this recommendation, the decision to vaccinate 
against serotype B is provider discretion.      
Attitude, Political, Legal, and Ethical Considerations  
 Despite efforts to improve vaccination rates, one-fifth of American children classified in 
the highest at-risk category have not received the meningitis vaccine (NMA, 2016).  
Furthermore, given the lack of a universal meningitis schedule, less than 30% of children have 
received a booster dose extending immunity.  Factors that may influence willingness to 
immunize include individual state policies, higher educational requirements of vaccination, and 
clinician/parental beliefs and attitudes towards the vaccine (Elam-Evans et al., 2014).  For 
example, when school districts require proof of vaccination, inoculation rates improve and 
disease rates are subsequently reduced (Omer et al., 2009).  
 Policy makers may challenge a mandatory vaccination program due to ethical concerns of 
violating personal autonomy.  However, as with other established vaccine mandates already in 
place (such as Tdap, MMR, and polio), parents maintain the right to decline vaccination due to 
personal or religious beliefs.  As a result of this, the child may be unable to attend public school 
or may contract illness during periods of disease outbreak (Alaska Immunization Program, 
2016).    
 According to Alaska Statute, all children entering into the public educational system 
providing education from preschool to the 12th grade must demonstrate proof of immunization 
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against diphtheria, tetanus, polio, pertussis, measles, mumps, hepatitis A, hepatitis B, rubella, 
and varicella (Alaska State Legislature, 2015).  The decision to waive required vaccinations is 
acceptable only if vaccination is deemed more harmful than going without vaccination.  This 
decision must be documented by a medical doctor, doctor of osteopathy, physician assistant, or 
advanced nurse practitioner licensed to practice in the State of Alaska.  Vaccination waiver is 
also acceptable if the child has a signed affidavit by parent/guardian stating that vaccination is in 
direct violation of religious beliefs and membership pertaining to a certain denomination or 
church.  A mandatory meningitis vaccination schedule would follow current legislative policy in 
this respect.  
 It’s also likely that public fear surrounds a mandatory vaccination schedule.  Much of this 
stems from inadequate distribution of vaccine information amongst the public.  Misconceptions 
about vaccines exist; unfounded allegations such as vaccines causing autism have reduced 
vaccination rates (Omer et al., 2009).  Vaccine refusal relating to personal belief rather than 
contraindication to vaccination increases the potential for disease outbreak.   
 Despite known efficacy of vaccines preventing disease, the meningitis vaccine continues 
to be optional.  A mandatory vaccination schedule incorporated into the current Alaska State 
vaccination policy to reduce disease outbreak and prevent the morbidity and mortality associated 
with meningococcal illness is a public health priority.  Advocacy for practice change that meets 
current standards of care is a professional responsibility.  Political advocacy promotes health, 
wellness, and a means of preventing illness for patients, families and communities (American 
Association of Nurse Practitioners, 2012).  Activism also advances the nurse practitioner’s role 
and professional title beyond direct patient service.  As outlined by the Master’s Essentials for 
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the American Association of Colleges of Nursing (2011), this project integrated policy change, 
professional leadership, and quality improvement essentials for education.  
Conformity of Programs  
 The Center for Disease Control and Prevention and the Advisory Committee on 
Immunization Practices, currently recommend the first dose of Quadrivalent Meningococcal 
Vaccine be administered between the ages of 11-12 years with a booster dose administered 
between 16-18 years (2016).  There must be a minimum of four years separating the first and 
second dose of Menactra, although separation of five years when following the recommended 
vaccination schedule is considered ideal (Sanofi Pasteur Inc., 2014).  Timing the vaccination in 
this way reduces meningococcal-related fatalities and life-long sequelae during the period the 
child is most at risk for disease (CDC, 2015; Elam-Evans et al., 2014; NMA, 2016). 
Furthermore, vaccination offers outbreak reduction to communities, protecting against serotypes 
C and Y, which have an increased national and state prevalence (CDC, 2015; IAC, 2016; NMA, 
2016). 
 According to the Immunization Action Coalition (2017), 14 of 51 states (including the 
District of Columbia) report required meningitis vaccine policy with at least one dose of 
meningitis vaccine administered to a child by Grade seven.  Delaware requires one dose 
administered by the ninth grade.  Twelve of 51 states require at least one dose administered by 
Grade 7, with the final dose given by Grade 12.  There was slight variation reported between 
states as to when the child receives the first vaccination.  Some states reported either Grade 6 or 
Grade 7.  State policies that were different from one another (administration of one dose vs. two 
doses) were divided into separate categories in order to prevent an over estimation of totals.  
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Alaska does not have a meningitis vaccination mandate in place. Figure 1 depicts the national 
status of states with regard to mandatory meningitis vaccine schedules.  
 
     Figure 1.  US meningitis vaccine mandate by state.   
 
 According to the Immunization Action Coalition (2017), 15 of 51 states require that 
students entering colleges or universities be educated only about meningitis prevention 
(transmission and vaccination).  Twenty-two of 51 states require that students be educated about 
meningitis and provide proof of vaccination or a waiver.  West Virginia requirements vary and 
are determined by each university separately.  Slight variation exists between states that require 
all students to be educated as opposed to only those residing in campus housing.  State policies 
that were different from one another (education only vs. education and proof of 
vaccination/waiver) were divided into separate categories in order to prevent an over estimation 
of totals.  Alaska policy dictates that students attending college and universities are educated on 
meningococcal prevention.  Proof of vaccination and/or acknowledgement of education materials 
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is required to attend college or reside in campus housing.  Figure 2 summarizes the state 
education requirements.          
 
     Figure 2. Meningitis prevention mandates for colleges & universities.    
 
Equity of Distribution 
 State-implemented mandatory dosing schedules take into account exposure risk related to 
school attendance and participation in sports programs through the collegial level, while 
simultaneously reducing racial disparities that may exist with vaccine availability (National 
Foundation for Infectious Diseases, 2010).  States with mandatory vaccination schedules have 
funding in place to reduce out-of-pocket cost to patients.  Alaska utilizes the Alaska Vaccine 
Assessment Program (AVAP) and the Vaccines for Children (VFC) programs, which offer low-
cost vaccines to children and some adult patients in the State (Alaska Immunization Program 
[AIP], 2016).  
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 During 1989 to 1992, there was a nationally declared measles crisis (CDC, 2014).  Over 
half of children infected with measles were not vaccinated despite having seen a health care 
provider.  Because of this outbreak, legislation created the VFC program.  The VFC program 
makes vaccination accessible regardless of ability to pay for children 18 years of age and 
younger.  Each state has a VFC coordinator responsible for keeping record of provider 
enrollment into the program.  Institutions automatically enrolled are public health agencies, 
federally qualified health centers, and rural health clinics.  Any medical establishment can 
qualify for VFC supplied vaccines, even if the provider does not see Medicaid eligible patients. 
Patients that are qualified for VFC vaccines must at minimum be 18 years of age or younger. 
Other criteria that must be met include being Medicaid eligible, underinsured/without insurance, 
Alaska Native or American Indian, and/or meeting eligibility criteria the Alaska Vaccine 
Assessment Program.  Any child receiving a vaccination meeting at least one of these criteria is 
supplied with VFC vaccine, which in fact makes all children eligible.  Vaccine administration 
fees vary depending on eligibility criteria, but a state mandated maximum is set for VFC.  This 
federal program covers children receiving the Menactra vaccine who are 18 years of age and 
younger.  The term state-supplied vaccine is interchangeably used with federally supplied 
vaccine, as the vaccine itself is provided to states by the federal VFC program.            
 Enrollment in the Alaska Vaccine Assessment Program by healthcare payers (such as 
private insurance agencies) allows for federally funded vaccine to be distributed to AVAP 
enrolled healthcare providers.  Healthcare payers that have opted out of AVAP program in 2017 
include Medicare, Medicaid, Tricare, and Prudential Insurance Company (AVAP, 2017). 
Healthcare providers opt in to the AVAP program, making vaccination available to adults more 
affordable.  In the State of Alaska, a fee of $0.60 per adult is charged with a minimum of 50 
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adults paid for by each facility.  Young adults between 19 to 20 years of age, seeing an AVAP 
opt-in provider with a qualifying healthcare payer or an underinsured status, are eligible to 
receive federally supplied Menactra vaccine (AVAP, 2017).          
Immunization Strategy 
 It is imperative to take what is known about the ramifications of meningitis as well as the 
age of the target population most at risk and incorporate this into an inoculation strategy. 
Incorporating a mandatory meningitis vaccination schedule into the timeframe when other 
optional vaccines offered to adolescents, such as HPV, would likely be effective.  
 The effectiveness is enhanced when the timeframe of vaccination is compared to 
characteristics of the adolescent population.  This is because the adolescent can be difficult to 
reach in terms of illness prevention.  According to Humiston and Rosenthal (2005), the 
healthcare of the adolescent does not revolve around vaccine related appointments.  Instead, they 
are being seen for sports physicals and acute injuries.  The opportunity to vaccinate may not be 
recognized or addressed during a brief illness-focused visit.  The literature suggests vaccination 
alone is not enough to prompt the adolescent into seeing a healthcare provider, unless his/her 
school requires proof of vaccination (Humiston & Rosenthal, 2005).  
Use of Resources  
 As reported by the CDC, IAC, and the WHO, vaccinating at risk populations is 
beneficial.  Continued surveillance of outcomes following a meningococcal vaccine mandate is 
essential (WHO, 2016).  It is unclear whether efforts to improve current legislation on the topic 
of mandatory meningitis vaccination in Alaska are underway.  Currently, Alaskan universities 
are only required to educate students on meningitis inoculation benefits.  This leaves opportunity 
for parents and children to decline vaccination, relying on personal feelings for decision making 
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as opposed to established facts that have led to a national standard of care.  In order to overcome 
existing challenges to implementing a mandatory meningococcal vaccination schedule, an inter-
professional approach would be useful.  Identifying resources for meningococcal vaccine 
knowledge including disease burden, vaccine characteristics, surveillance, and immunization 
strategy to inform the public is an important step in moving towards a vaccine mandate.  This 
strategy could utilize a variety of Alaska-based resources to include Department of Health and 
Social Services, the Alaska Immunization Program, the Alaska Epidemiology Department, the 
Alaska Nurse Practitioner Association, public health and school-based resources.  National 
resources to implement such a mandate are also available, such as the CDC and ACIP.  It 
appears this approach would coincide with mandated vaccination programs already in place.  
Cost 
 As previously mentioned, the AVAP and the VFC program already offer affordable 
vaccines to Alaskans.  It is undetermined at this point what the financial implications of 
implementing a statewide vaccination policy for meningitis would be.  Absolute cost of a 
vaccine program, and the immediate estimation of cost, may be prioritized over the projected 
value of cost reduction by illness prevention when such programs are being evaluated (Erickson 
et al., 2005).  A projected value-to-cost ratio approximates cost in relation to value of a program 
over time.  Cost benefit analysis is used to determine vaccine policy, but often does not include 
the quality of life issues that create significant burden for families with a child devastated by 
bacterial meningitis.  These important considerations must be addressed to challenge policy. 
Understanding themes presented in the literature thus far, one can estimate that by incurring an 
immediate vaccine cost to reduce rates of future disease, personal and national financial burden 
will also decrease.  Additionally, the Menactra vaccine is already available and promoted by the 
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Alaska State vaccine program, therefore enhanced costs are not anticipated at the state level. 
Federal costs may increase as vaccination rates increase, but would be mitigated by the reduction 
in disease outbreak as demonstrated by the US military meningitis vaccination program.          
Effectiveness Evaluation  
 The World Health Organization (2015) reports that routine meningitis vaccination 
improves herd protection, which in turn, leads to a reduction in the financial, physical, and 
emotional challenges placed on individuals, families, and society.  Mandatory vaccination policy 
is recommended for areas with high incidence of the disease.  Understanding trends of infection 
using sophisticated surveillance programs to monitor and record such data, such as those used to 
monitor the occurrence of other vaccine preventable diseases, is essential to determine the need 
for vaccine mandates.  The Alaska’s State Epidemiology program provides such data annually.  
 As discussed earlier, the US military has reduced the likelihood of outbreak and 
transmission between personnel living in close quarters after implementing a mandatory 
meningitis vaccine policy (Broderick, 2015).  Since this requirement has begun in the 1970s, 
meningitis has been successfully reduced by over 90%.  One vaccination is required prior to 
military entry.   
Methods 
Project Design  
 Advocacy.  The project leader met with Craig Public Health twice over the course of this 
project to gather program feasibility information.  From this interaction, a point of contact from 
the Alaska Immunization Program was identified.  The AIP contact provided information on the 
VFC and AVAP programs and nonbiased feedback and guidance on project materials.  
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 Senator Cathy Giessel was contacted at the Alaska Nurse Practitioner Association’s 
annual conference.  The timeline for this project originally centered on completion of a 
legislative presentation.  It was determined that legislative contact would take place between 
January and May 2017.  However, email correspondence with Senator Cathy Giessel revealed 
that the Alaska legislative body was focused on Medicaid policy and would not have an 
opportunity to discuss a mandatory meningitis vaccine schedule this year.  While communication 
with health policy officials did not yield a viable option to present the topic to legislators, it 
allowed exposure to health policy practices.  A policy brief was created to address this barrier. 
The policy brief was electronically distributed to the legislative health care committee with a 
brief survey asking one question regarding support of a mandatory meningitis vaccination policy.  
With the priority of the Health Committee on Medicaid policy, the objective of this project 
shifted to focus on the other goal of widespread education and increasing public awareness.               
 Community awareness.  The project’s focus of increasing awareness of meningitis and 
the vaccination prevention strategy was initiated for both community members and health care 
providers.  A community education presentation was created for the Prince of Wales (POW) 
Community Health Fair as a means to disseminate information.  The Community Fair occurred 
on April 8, 2017.  
 Informational delivery utilized at the Prince of Wales Community Health Fair was 
primarily done by direct interaction with the public.  The project leader secured a meningitis 
booth.  Meningitis awareness stickers, pens, and magnets with meningitis awareness themes 
were provided as promotional materials.  A large two and one half foot by eight-foot meningitis 
banner was displayed at the booth.  A teaching tool was constructed using cupcakes.  Fifteen 
percent of 30 cupcakes were frosted with red icing demonstrating the number of children killed 
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by meningitis, 19% of the 30 cupcakes were sprinkled with red and pink sprinkles to portray the 
number of children affected by permanent neurologic and musculoskeletal dysfunction, and the 
remaining cupcakes were left frosted white to show the remaining healthy children.  POW 
community members stopping at the meningitis booth were offered a brief survey following the 
educational offering.  
Professional Education  
 The health care education included a “meningitis education bundle” created as a resource 
for healthcare professionals on Prince of Wales Island.  PeaceHealth Medical Group and Craig 
Public Health received a copy of the bundle.  A 25-minute educational presentation for 
PeaceHealth Medical Group was provided.  Craig Public Health will receive the same 
information within the next three months.  Supplemental materials that accompanied the 
meningitis bundle included 10 vaccination reminder magnets, 20 meningitis awareness stickers, 
and five meningitis awareness pens.   
Data collection   
 Community education outcomes.  The 2017 Community Health Fair data collection 
was performed using a simple post-test design that consisted of nominal data with yes, no, or 
maybe answers to a series of questions pertaining to the informational content at the booth and 
willingness to vaccinate.  An optional comments section was provided at the end of the survey 
for participant feedback (appendix B). Inclusion criteria for participants included (a) age 18 years 
or older, (b) willingness to complete the survey, (c) participant had at least one educational 
statement on meningitis and/or vaccination delivered to him/her while at the meningitis booth.  
 Professional education outcomes.  The Alaska Legislative Health Committee member’s 
survey utilized a simple post-test design that consisted of nominal data, yielding yes, no, or 
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maybe answers to a single question regarding willingness to support a mandatory vaccination 
schedule for bacterial meningitis.  An optional comments section left at the end of the survey for 
participant feedback (Appendix A).  
 Inclusion criteria for participants included (a) being an active member of the Alaska State 
legislature and (b) a willingness to participate in the survey.  Members were selected from the 
Legislative Directory found on akleg.gov.  
Barriers and Challenges  
 The primary barrier to implementing the advocacy portion of this project was getting 
face-to-face time with the State’s legislative members.  Contact was made with Senator Giessel 
January 20, 2017, who made it clear that the agenda for the senate would focus only on Medicaid 
policy.  The health committee was unable to address the topic of meningitis vaccination policy 
within the timeframe of the graduate project.  Because of this setback, the primary goal for this 
project transitioned to expanding community health using existing standards of care.  
 The alteration in project design and delivery caused the outcomes measured to change.   
Other Considerations 
 Development of the “meningitis education bundle” occurred in an elective graduate 
course taken spring semester of 2017.  The course revolved around adult learning principles and 
curriculum development.  The topic of meningitis was integrated into course assignments where 
feedback from the professor and other students helped to promote the development of an 
excellent education bundle.   
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Human Subject Status 
 The University of Alaska Anchorage Institutional Review Board approved the project 
prior to project implementation.  Survey data was collected using anonymous human subjects. 
Data was only collected from voluntary participants who met the inclusion criteria discussed 
previously.  There were no patient identifiers collected or documented.  
Project Outcomes 
 The primary objective for data analysis was to discern the degree of support from a small 
group of state policy leaders for a mandatory meningitis vaccination schedule.  These data were 
collected to support future legislative advocacy and community awareness initiatives on this 
topic.  The secondary objective was to increase community awareness of meningitis and its 
prevention.  Questions were posed to discern whether educational intervention was beneficial in 
raising vaccine rates and gaining support for a required meningitis vaccine policy.     
Data Analysis  
 Data collection was performed using a simple post-test design and nominal 
quantification.  One of nine members of the Alaska Legislative Health Committee responded 
indicating an answer of maybe.  The remaining eight members did not respond to the survey.  
The survey remained open for 12 days.  Table 1 shows the distribution of responses.   
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Table 1. 
Survey Responses from Legislative Health Committee: Would you support a mandatory 
meningitis vaccination schedule?    
 Members Yes No Maybe Did not 
respond 
 Subject 1   1  
 Subject 2    1 
 Subject 3    1 
 Subject 4    1 
 Subject 5    1 
 Subject 6    1 
 Subject 7    1 
 Subject 8    1 
 Subject 9    1 
Sum  9   1 8 
 
 Participants in the POW health fair survey met the inclusion criteria previously outlined. 
The meningitis awareness information was available to the public for six hours during the fair.  
Eighty-two participants stopped at the booth, 68 participants received meningitis educational 
statements, and 65 participants received educational statements and completed a POW health fair 
survey.  A non-biased data collector documented the number of people who stopped at the booth, 
how many received educational statements, and provided assurance that inclusion criteria were 
met for the survey.  All participants in the survey met the inclusion criteria (18 years of age or 
older and having had at least one educational statement).  Questions included in the survey were: 
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1. Would you choose to vaccinate against meningitis?  
2. If yes, did the education you received today influence your decision to vaccinate? 
3. If no, why would you choose not to vaccinate?  
4. Would you support a required meningitis vaccine for children attending public school in 
Alaska?   
 The answer to question number three was a write-in response.  A comments section at the 
end of the survey was included.  In order to reduce researcher influence on survey answers, the 
participants were provided privacy to complete the survey. 
 Fifty-six participants indicated that they would choose to vaccinate against meningitis, 
five responded with a no, and four indicated a response of maybe.  Fifty-two respondents 
indicated that they felt the educational offering influenced their decision to vaccinate, five did 
not feel the education influenced their decision, and nine indicated a response of maybe. 
Individuals indicated that they did not want to vaccinate against meningitis due to side effects of 
the vaccine, a previously vaccinated status (for either themselves or their children), or an anti-
vaccine cultural influence.  Fifty-three participants were in favor of a required meningitis vaccine 
for children attending public school, five were not, and eight indicated a response of maybe.  For 
respondents who were either not in favor of vaccination or in favor of a required vaccination for 
children attending public school, additional comments were directed towards the safety, efficacy, 
and financial aspects of a required vaccine program.  Additionally, maintaining personal 
autonomy in vaccination policy was also a concern.  Figures 3, 4 and 5 reflect survey response 
percentages. 
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     Figure 3. Question 1: Would you choose to vaccinate against meningitis?   
 
 
      Figure 4. Question 2: If yes, did the education that you received influence your decision to 
vaccinate?   
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     Figure 5. Question 3: Would you support a required meningitis vaccine for children attending 
public school in Alaska?   
 
 A total of 10 bumper stickers, 38 vaccination reminder magnets, 74 meningitis awareness 
stickers, and 18 meningitis awareness pens were provided to the public.  Additionally, there were 
several occasions in which education was provided to adolescents and young adults regarding 
meningitis vaccination, however, they did not meet inclusion criteria for the survey.  The 
cupcake display showing the percentage of those affected with meningitis death rates and 
permanent disabilities was successful based upon feedback gained from those who received 
education at the booth.  The cupcake-teaching tool helped draw children and parents to the 
meningitis booth.  Appendices C through G provide POW health fair material.   
Data Synthesis   
 The Alaska Legislative Health Committee survey provided a single response of maybe.  
Although a comprehensive health policy brief was provided, committee members did not 
participate in the survey.  It is unclear if the legislature would support incorporation of a required 
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meningitis vaccination into existing Alaska vaccine policy.  There are many unknown variables 
as to why participation was low, but likely related to the sole focus on Medicaid reform.    
 The POW annual health fair survey data concluded that community awareness efforts 
were successful.  Education to the public was effective; the majority of participants who were 
surveyed supported a required vaccine schedule for children attending public school.  Many 
favorable comments were made that indicated support for future vaccine awareness initiatives.  It 
is likely that efforts similar to this would be successful in other locations of Alaska.    
Dissemination 
 The project was developed and implemented over a nine-month period concluding April 
2017.  The project leader has a passion to move mandatory meningitis vaccination into law. 
Efforts to advocate for a mandatory meningitis vaccination schedule will continue until Alaska 
incorporates mandatory meningitis vaccination into existing vaccine policy.  
 Collaboration with Marianne Murray with the University Alaska Anchorage School of 
Nursing offered an opportunity to disseminate meningitis awareness information to Theta 
Omicron Chapter of Sigma Theta Tau International.  A date for this has yet to be solidified.   
Change in Practice 
 Evidence found in the literature supports a nationally established standard of care 
pertaining to meningitis vaccination.  Quadrivalent vaccination demonstrates safety and efficacy 
in preventing illness by meningitis serotypes most responsible for causing catastrophic illness.  
The Advisory Committee on Immunization Practices and the Centers for Disease Control and 
Prevention has established a recommended vaccination schedule.  To enhance accessibility, the 
federal VFC program includes the meningococcal vaccine and is available to children 18 years 
and younger (along with other required vaccinations).  As depicted previously, 27 of 51 US 
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states have a mandatory meningitis vaccination mandate in place to some degree (IAC, 2017).  
Out of 51 states, 38 have a meningitis prevention strategy for colleges and universities, which 
either does or does not include proof of vaccination or waiver.  Combined, a total of 44 states 
have some form of meningitis prevention policy in place.  Alaska has yet to incorporate a 
meningitis vaccination mandate into existing vaccination policy.  Alaska requires that students 
be educated on meningitis prevention when entering onto a college campus, but vaccination is 
optional.  Moving towards national uniformity in meningitis prevention practices and global 
health, Alaska should incorporate a mandatory meningitis vaccination schedule into existing 
vaccination policy.  This would alter existing practice to a small degree, as there are already 
seven required vaccinations in Alaska for children to attend public school.     
Recommendations for Future Study  
 There is a preponderance of literature with strong evidence-based support for the 
recommendations made in favor of a meningitis vaccination mandate.  It would be reasonable to 
evaluate mandates in other states that have already put mandatory meningitis vaccination in 
place to determine the feasibility and long-term implications this type of program might create.  
Monitoring epidemiologic data pre and post vaccine mandate to evaluate policy change effects in 
meningitis occurrence would be beneficial.  Evaluating these data could provide further evidence 
that required vaccination improves disease rates, as this was suggested by the literature. 
 Additionally, literature on the topic should be updated annually to ensure accuracy of 
information.             
 Community educational endeavors should extend beyond Prince of Wales Island.  
Options to expand this initiative in Alaska include creating a public service announcement, 
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building a meningitis prevention website or Facebook page, and holding direct public 
educational events in other areas.  
Conclusion 
Professional Standards  
 Meeting qualifying criteria as outlined by the Master’s Essentials within the American 
Association of Colleges of Nursing was foundational for the structure of this project.  This 
project contains a scientific basis for illness prevention and aims to promote health and wellness, 
as dictated by national standards of care.  The primary goal for this project was to incorporate a 
mandatory meningitis vaccination schedule in already existing Alaska vaccine policy.  The 
process in which to achieve this goal involved professional leadership within the discipline, 
advocacy on a state level, and an understanding for how policies influence healthcare decision-
making.  This served as the advocacy and leadership component of the project.  
 The secondary goal for this project was to increase general awareness of meningitis and 
its prevention within Alaska.  Achieving this goal required professional collaboration on various 
levels, designing creative strategies for informational dissemination, and addressing social 
determinants of health.  This served as the community health portion of the project focusing on 
population health outcomes.    
 Goals for graduate student education met through the design, implementation, and 
analysis of the project outcomes for this project successfully met the Master’s Essentials of 
Nursing Practice.  This project included analyzing existing evidence, drawing conclusions from 
such evidence, and applying the evidence to practice incorporating inter-professional 
collaboration, systems leadership, and clinical prevention and population health for improving 
the state’s health.  
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Summary 
 In conclusion, the project was not successful in moving mandatory meningitis 
vaccination into policy.  However, the project was successful in evaluating community 
likelihood to vaccinate and supporting a required vaccination schedule for public school 
attendance and demonstrating that community education may provide a basis for policy change. 
Further steps should be taken to advocate for implementing a meningitis vaccination policy in 
Alaska.  There should also be ongoing efforts to increase meningitis awareness within various 
Alaskan communities.      
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Appendix A 
Survey to Legislative Health Committee 
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Appendix B 
Survey to Community at 2017 POW Community Health Fair 
 
2017 POW Annual Health Fair 
Amanda  Hulstine BSN, RN, FNPS 
University Alaska Anchorage, Masters of Nursing Science 
Meningitis Awareness Health Fair Survey 
 
 1. Would you choose to vaccinate against meningitis? 
• Yes 
• No 
• Maybe  2. If YES, did the education that you received influence your decision to vaccinate? 
• Yes 
• No 
• Maybe  3. If NO, why would you choose NOT to vaccinate?    _________________________________________________________________________________________  4. Would you support a required meningitis vaccine for children attending public school in Alaska?  
• Yes 
• No 
• Maybe    Comments: 
 
 _________________________________________________________________________________________ 
 
 _________________________________________________________________________________________ 
  
 _________________________________________________________________________________________ 
 
 _________________________________________________________________________________________ 
 
VACCINE IMPLEMENTATION: ALASKA 2017 39 
Appendix C 
2017 POW Community Health Fair Meningitis Sticker 
 
 
Appendix D 
2017 POW Community Health Fair Bumper Sticker 
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Appendix E 
2017 POW Community Health Fair Meningitis Reminder Magnets 
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Appendix F 
2017 POW Community Health Fair Meningitis Pens 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VACCINE IMPLEMENTATION: ALASKA 2017 42 
Appendix G 
2017 POW Community Health Fair Meningitis Banner 
 
 
